MARKET

CBIO

CBIO

Catalyst Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.990
+0.630
+14.45%
Closed 16:00 04/08 EDT
OPEN
4.470
PREV CLOSE
4.360
HIGH
5.10
LOW
4.440
VOLUME
243.99K
TURNOVER
--
52 WEEK HIGH
10.78
52 WEEK LOW
3.430
MARKET CAP
83.06M
P/E (TTM)
-1.0854
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBIO stock price target is 21.00 with a high estimate of 23.00 and a low estimate of 20.00.

EPS

CBIO News

More
  • Catalyst Bio on go with late-stage study of MarzAA; shares up 9%
  • Seeking Alpha - Article · 2d ago
  • Catalyst Biosciences Announces Pivotal Phase 3 Study Design for MarzAA in Individuals with Hemophilia A or B with Inhibitors
  • GlobeNewswire · 2d ago
  • FDA OKs new hemophilia treatment
  • Seeking Alpha - Article · 04/01 17:51
  • How Much is Catalyst Biosciences, Inc.'s (NASDAQ:CBIO) CEO Getting Paid?
  • Simply Wall St. · 03/29 14:02

Industry

Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+2.82%

Hot Stocks

Symbol
Price
%Change

About CBIO

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
More

Webull offers kinds of Catalyst Biosciences Inc stock information, including NASDAQ:CBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBIO stock news, and many more online research tools to help you make informed decisions.